Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Strata Skin Sciences's Revenue for the
three
months ended in Dec. 2025 was €7.94 Mil. Strata Skin Sciences's average Accounts Receivable for the
three
months ended in Dec. 2025 was €3.25 Mil.
Hence, Strata Skin Sciences's Receivables Turnover for the
three
months ended in Dec. 2025 was 2.44.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Strata Skin Sciences Receivables Turnover Related Terms
Strata Skin Sciences Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Strata Skin Sciences's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:E2O vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Strata Skin Sciences's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strata Skin Sciences Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Strata Skin Sciences's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Strata Skin Sciences's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strata Skin Sciences (FRA:E2O) has a Receivables Turnover of 2.44 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Strata Skin Sciences and its competitors. According to the industry distribution chart, Strata Skin Sciences ranks #259 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 31.9%.
Is Strata Skin Sciences' Receivables Turnover too high?
Strata Skin Sciences' current Receivables Turnover is 2.44. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Strata Skin Sciences' value of 2.44 is 55.7% below this industry median. Based on the distribution chart, Strata Skin Sciences ranks #259 out of 812 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Strata Skin Sciences has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Strata Skin Sciences' Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Strata Skin Sciences ranks #259 out of 812 companies for Receivables Turnover. This puts Strata Skin Sciences in the upper half of its industry. The industry median Receivables Turnover is 5.51. Strata Skin Sciences' value of 2.44 is 55.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strata Skin Sciences's current Receivables Turnover of 2.44 is 55.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Strata Skin Sciences and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strata Skin Sciences's current Receivables Turnover is 2.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Skin Sciences stock overvalued right now?
Strata Skin Sciences (FRA:E2O) has a current Receivables Turnover of 2.44. The stock's GF Value™ is €1,380.95, compared to a current price of €3.76 — trading 99.7% below its estimated fair value. The current Receivables Turnover is 2.44 and 55.7% below the Medical Devices & Instruments industry median of 5.51. Strata Skin Sciences' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Strata Skin Sciences (FRA:E2O), the current Receivables Turnover is 2.44 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strata Skin Sciences (FRA:E2O) Overvalued in 2026?
Based on GuruFocus' analysis, Strata Skin Sciences stock appears to be undervalued.
The current stock price of €3.76 is trading 99.7% below its estimated GF Value™ of €1,380.95.
Key valuation signals for FRA:E2O:
Receivables Turnover: 2.44
GF Value™: €1,380.95 vs. price of €3.76 (99.7% below fair value)
Industry Position: 55.7% below the Medical Devices & Instruments median (#259 of 812)
No single metric tells the full story. See the FRA:E2O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver, and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
38GF Score
Get the complete analysis for FRA:E2O
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:E2O has been successfully added to your 
